PMAC at ASCO 2026

We are excited to share that PMAC will be actively contributing to ASCO 2026, presenting new data that reflect our commitment to advancing research in breast cancer.

This year, two members of our team will showcase important findings that bridge biology, clinical outcomes, and health disparities:

• Dr. Emily Podany

  Rapid Oral Presentation

  “Impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer”

  📅 May 31, 11:42 AM (Session 11:30 AM – 1:00 PM, Hall D1)

  
  

• Dr. Lorenzo Foffano Poster Presentation “Prognostic impact of PIK3CA amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer”

  📅 June 1, 1:30 – 4:30 PM (Poster Board 150)

Also check our e-abstract "Minimal residual disease ctDNA testing in metastatic breast cancer patients with no radiological evidence of disease: Potential clinical utility from real-world data” by Dr. Caterina Gianni

Why This Matters

Our work at ASCO highlights key dimensions of cancer research:

• The intersection between social determinants of health and tumor biology

• The growing role of liquid biopsy and genomic profiling in guiding clinical decisions

Meet the PMAC Team

If you are attending ASCO, we would love to connect.

Come speak with us to:

• Learn more about our ongoing research

• Explore collaboration opportunities

• Exchange ideas on how to accelerate progress in breast cancer care

Reach out or stop by during the sessions — we look forward to meeting you.